Cullinan Therapeutics, Inc.
CGEMNASDAQHealthcareBiotechnology
Latest quote
$15.53
+$0.07 · +0.45%
CGEM company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
GoAI Score
Hold
Valuation
25
Expensive
Sentiment
71
Bullish
Risk
38
Moderate Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Company profile
Company websiteCullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Nadim Ahmed
- Listed since
- Jan 8, 2021
- Employees
- 109
Market position
Day range
Current $15.53
52-week range
Current $15.53
- Open
- $15.48
- Previous close
- $15.46
- Volume
- 566.37K
- 0.57× average
- Average volume
- 998.37K
- Average daily volume
- Market cap
- 954.44M USD
- Beta
- -0.01
- Market reference 1
- 50-day average
- $19.2734
- -19.42% below average
- 200-day average
- $15.4997
- +0.20% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 525.52M USD
- P/E (TTM)
- -4.61×
- P/B (TTM)
- 2.97×
- P/S (TTM)
- 0×
- EV / EBITDA
- -2.39×
- Earnings yield
- -35.98%
- Free cash flow yield
- -28.76%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -53.80%
- Return on assets
- -49.04%
- Return on invested capital
- -58.74%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 10.25×
- Altman Z-score
- 10.06
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | 18.94M USD |
| Cost of goods sold | — | 306K USD | — | — | — |
| Gross profit | — | −306K USD | — | — | 18.94M USD |
| Research and development | 187.4M USD | 142.9M USD | 148.16M USD | 91.95M USD | 57.75M USD |
| Selling, general, and administrative | 54.25M USD | 53.71M USD | 42.49M USD | 40.19M USD | 29.15M USD |
| Operating expenses | 241.65M USD | 196.61M USD | 191.09M USD | −144.65M USD | 86.9M USD |
| Interest income | 22.21M USD | 29.66M USD | 21.63M USD | 6.61M USD | 477K USD |
| Depreciation and amortization | 311K USD | 306K USD | 310K USD | 93K USD | 53K USD |
| Operating income | −241.65M USD | −196.92M USD | −191.09M USD | 144.65M USD | −67.95M USD |
| Net income | −219.88M USD | −167.38M USD | −153.16M USD | 111.21M USD | −65.57M USD |
Company facts updated Oct 11, 2026.
Earnings
- EPS beat rate
- 73%
- 8 beats, 3 misses, 0 met estimates
- Average EPS surprise
- +6.14%
- 11 comparable reports
- Latest EPS result
- -0.81
- Estimate -0.8 · Miss by 1.34%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$34.75
123.76% upsideRating distribution
8 ratingsRecent analyst actions
CGEM news
CGEM peers
ETFs holding CGEM
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI43.14M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM24.68M0.03%78.74B USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI19.22M0.19%9.87B USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF13.74M0.01%95.4B USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO7.68M0.04%18B USD0.06%$112.66+0.50%
iShares Biotechnology ETFIBB5.64M0.05%10.82B USD0.44%$206.49+3.00%
Dimensional - US Small Cap ETFDFAS5.29M0.02%33.87B USD0.31%$78.35+0.32%
Fidelity Enhanced Small Cap ETFFESM4.8M0.07%6.41B USD0.28%$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 43.14M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $381.94+0.63%
iShares Russell 2000 ETFIWM- Market value
- 24.68M
- Weight
- 0.03%
- AUM
- 78.74B USD
- Expense ratio
- 0.19%
- Price / 1D
- $278.94+0.49%
State Street SPDR S&P Biotech ETFXBI- Market value
- 19.22M
- Weight
- 0.19%
- AUM
- 9.87B USD
- Expense ratio
- 0.35%
- Price / 1D
- $153.77+3.00%
Vanguard Extended Market ETFVXF- Market value
- 13.74M
- Weight
- 0.01%
- AUM
- 95.4B USD
- Expense ratio
- 0.05%
- Price / 1D
- $235+0.80%
Vanguard Russell 2000 ETFVTWO- Market value
- 7.68M
- Weight
- 0.04%
- AUM
- 18B USD
- Expense ratio
- 0.06%
- Price / 1D
- $112.66+0.50%
iShares Biotechnology ETFIBB- Market value
- 5.64M
- Weight
- 0.05%
- AUM
- 10.82B USD
- Expense ratio
- 0.44%
- Price / 1D
- $206.49+3.00%
Dimensional - US Small Cap ETFDFAS- Market value
- 5.29M
- Weight
- 0.02%
- AUM
- 33.87B USD
- Expense ratio
- 0.31%
- Price / 1D
- $78.35+0.32%
Fidelity Enhanced Small Cap ETFFESM- Market value
- 4.8M
- Weight
- 0.07%
- AUM
- 6.41B USD
- Expense ratio
- 0.28%
- Price / 1D
- $45.46+0.46%
Continue in GoAI
Research CGEMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.